|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Synvista Therapeutics, Inc |
|---|---|
| Information provided by: | Synvista Therapeutics, Inc |
| ClinicalTrials.gov Identifier: | NCT00043836 |
Purpose
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.
| Condition | Intervention | Phase |
|---|---|---|
|
Heart Failure, Congestive Dyspnea Pulmonary Edema |
Drug: ALT-711 |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study |
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, North Carolina | |
| Wake Forest University Baptist Medical Center, Department of Cardiology | |
| Winston-Salem, North Carolina, United States, 27157-1045 | |
| United States, South Carolina | |
| Medical University of South Carolina and Ralph H. Johnson VA Medical Center | |
| Charleston, South Carolina, United States, 29425 and 29401 | |
| Principal Investigator: | Dalane W Kitzman, MD | Associate Professor of Medicine and Cardiology, Wake Forest University Baptist Medical Center |
| Principal Investigator: | Michael R Zile, MD | Charles Ezra Daniel Professor of Medicine, Medical University of South Carolina |
More Information
| ClinicalTrials.gov Identifier: | NCT00043836 History of Changes |
| Other Study ID Numbers: | ALT-711-0214 |
| Study First Received: | August 14, 2002 |
| Last Updated: | September 1, 2009 |
| Health Authority: | United States: Food and Drug Administration |
|
ejection fraction exercise tolerance heart failure, congestive quality of life |
|
Dyspnea Edema Heart Failure Pulmonary Edema Heart Failure, Diastolic Respiration Disorders |
Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Heart Diseases Cardiovascular Diseases Lung Diseases |